Pharminox Ltd, a private oncology R&D company backed by IP Group, is to carry out joint research into novel small molecule chemotherapeutics with Schering-Plough.
A spin-out from Oxford University is looking to attract the attention of equity investors and pharmaceutical companies by focusing on the discovery and development of small molecules to treat cancer
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.